Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Toronto

$25,000.00

Rational design of non-immunogenic elastin-based materials for applications in drug delivery

FY 2016-17

Summary
Successful cancer chemotherapy requires that the powerful drugs which can reduce and eliminate tumours reach their intended target. Because these drugs are usually toxic, it is also essential that as little as possible is released into healthy parts of the body in order to limit adverse side effects. For these reasons, research scientists have been trying to develop ""drug delivery vehicles"" which act like trojan horses that can travel safely through healthy tissues and smuggle cancer drugs into tumours, where they are released over a prolonged period of time. These vehicles are tiny (nanometer-sized) particles that can travel through blood vessels and penetrate deep into tumours. They are made either of synthetic materials or of natural molecules such as lipids, which already exist in our bodies. However, important problems must be solved before these approaches become useful in cancer therapies. On the one hand, the synthetic particles developed to this date tend to elicit an immune response (inflammation), which results in the encapsulation of the vehicles in inert tissue, effectively ""burying"" and disabling them. On the other hand, natural, lipid-based vehicles tend to release their cargo too quickly, limiting their effectiveness. In this project, a team of research scientists in Toronto is working with a company in Vancouver to pilot a new approach whereby a protein called elastin is used as the primary ingredient in drug delivery particles. Elastin does not cause any inflammation, because it is already found in large amounts in our skin, lungs, major arteries, and other elastic tissues (indeed, it is the very presence of elastin that makes these tissues extensible and elastic). In addition, it has also already been shown that elastin-based materials, which are human-like but not taken from humans, are capable of holding anti-cancer drugs. The aims of this project are (1) to tailor the size of elastin-based particles so that they can be injected intraveneously and (2) to demonstrate that these particles can be loaded with a variety of cancer drugs. If successful, this work will provide a new tool to fight cancer as well as new technology that will benefit the canadian economy.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
492839-2015
Name nom
Pomès, Régis
Department département
Biochemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Rational design of non-immunogenic elastin-based materials for applications in drug delivery
Keyword
NSERC
Application summary
Successful cancer chemotherapy requires that the powerful drugs which can reduce and eliminate tumours reach their intended target. Because these drugs are usually toxic, it is also essential that as little as possible is released into healthy parts of the body in order to limit adverse side effects. For these reasons, research scientists have been trying to develop ""drug delivery vehicles"" which act like trojan horses that can travel safely through healthy tissues and smuggle cancer drugs into tumours, where they are released over a prolonged period of time. These vehicles are tiny (nanometer-sized) particles that can travel through blood vessels and penetrate deep into tumours. They are made either of synthetic materials or of natural molecules such as lipids, which already exist in our bodies. However, important problems must be solved before these approaches become useful in cancer therapies. On the one hand, the synthetic particles developed to this date tend to elicit an immune response (inflammation), which results in the encapsulation of the vehicles in inert tissue, effectively ""burying"" and disabling them. On the other hand, natural, lipid-based vehicles tend to release their cargo too quickly, limiting their effectiveness. In this project, a team of research scientists in Toronto is working with a company in Vancouver to pilot a new approach whereby a protein called elastin is used as the primary ingredient in drug delivery particles. Elastin does not cause any inflammation, because it is already found in large amounts in our skin, lungs, major arteries, and other elastic tissues (indeed, it is the very presence of elastin that makes these tissues extensible and elastic). In addition, it has also already been shown that elastin-based materials, which are human-like but not taken from humans, are capable of holding anti-cancer drugs. The aims of this project are (1) to tailor the size of elastin-based particles so that they can be injected intraveneously and (2) to demonstrate that these particles can be loaded with a variety of cancer drugs. If successful, this work will provide a new tool to fight cancer as well as new technology that will benefit the canadian economy.